As of 2025-07-02, the Relative Valuation of Enanta Pharmaceuticals Inc (ENTA) is (76.89) USD. This relative valuation is based on P/E multiples. With the latest stock price at 7.70 USD, the upside of Enanta Pharmaceuticals Inc based on Relative Valuation is -1098.6%.
The range of the Relative Valuation is (65.03) - (87.49) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 13.0x - 23.6x | 18.0x |
| Forward P/E multiples | 14.4x - 19.4x | 16.1x |
| Fair Price | (65.03) - (87.49) | (76.89) |
| Upside | -944.5% - -1236.2% | -1098.6% |
| Date | P/E |
| 2025-07-02 | -1.79 |
| 2025-07-01 | -1.71 |
| 2025-06-30 | -1.68 |
| 2025-06-27 | -1.66 |
| 2025-06-26 | -1.67 |
| 2025-06-25 | -1.65 |
| 2025-06-24 | -1.62 |
| 2025-06-23 | -1.58 |
| 2025-06-20 | -1.59 |
| 2025-06-18 | -1.60 |
| 2025-06-17 | -1.56 |
| 2025-06-16 | -1.61 |
| 2025-06-13 | -1.66 |
| 2025-06-12 | -1.64 |
| 2025-06-11 | -1.76 |
| 2025-06-10 | -1.68 |
| 2025-06-09 | -1.66 |
| 2025-06-06 | -1.66 |
| 2025-06-05 | -1.60 |
| 2025-06-04 | -1.58 |
| 2025-06-03 | -1.59 |
| 2025-06-02 | -1.39 |
| 2025-05-30 | -1.31 |
| 2025-05-29 | -1.37 |
| 2025-05-28 | -1.30 |
| 2025-05-27 | -1.29 |
| 2025-05-23 | -1.29 |
| 2025-05-22 | -1.28 |
| 2025-05-21 | -1.28 |
| 2025-05-20 | -1.35 |
| 2025-05-19 | -1.32 |
| 2025-05-16 | -1.28 |
| 2025-05-15 | -1.19 |
| 2025-05-14 | -1.15 |
| 2025-05-13 | -1.16 |
| 2025-05-12 | -1.23 |
| 2025-05-09 | -1.17 |
| 2025-05-08 | -1.18 |
| 2025-05-07 | -1.12 |
| 2025-05-06 | -1.12 |
| 2025-05-05 | -1.21 |
| 2025-05-02 | -1.32 |
| 2025-05-01 | -1.34 |
| 2025-04-30 | -1.35 |
| 2025-04-29 | -1.28 |
| 2025-04-28 | -1.25 |
| 2025-04-25 | -1.24 |
| 2025-04-24 | -1.26 |
| 2025-04-23 | -1.24 |
| 2025-04-22 | -1.22 |